Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Type 1, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.43 (2.59%)
Data as of 03/29/17 2:20 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $17.02 with a 52 week high of $20.74 and a 52 week low of $13.06.
Recent NewsMore >>
Audentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical Chart Review Of Patients With X-Linked Myotubular Myopathy (XLMTM)
Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1 / 2 Run-in Study of Patients with Crigler-Najjar Syndrome
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Thomas Soloway
SVP and Chief Financial Officer
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.